# Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response.

> **NCT02118051** · PHASE3 · COMPLETED · sponsor: **Instituto de Investigacion Sanitaria La Fe** · enrollment: 234 (actual)

## Conditions studied

- Infertility

## Interventions

- **DRUG:** Ganirelix 0.25 mg.
- **DRUG:** Recombinant choriogonadotropin alfa
- **DRUG:** Micronized natural progesterone.

## Key facts

- **NCT ID:** NCT02118051
- **Lead sponsor:** Instituto de Investigacion Sanitaria La Fe
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2017-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02118051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02118051, "Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response.". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT02118051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*